InDex Pharmaceuticals discontinues the development of cobitolimod
26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that the company will discontinue development of their drug candidate cobitolimod. Thorough analysis of the data from Induction Study 1 of the phase III program CONCLUDE has not provided any results justifying continued development.Induction Study 1 of the phase III program CONCLUDE, evaluating cobitolimod as a new treatment for moderate to severe left-sided ulcerative colitis, was discontinued on November 21, 2023 based on the advice from an independent Data Monitoring Committee (DMC). The
CONCLUDE CDE and EPLASS CDE meet SOC 2 and C5 security requirementsMunich, 26 February 2024 – Thinkproject, the leading European SaaS provider of solutions for the construction industry, has received an official SOC 2 attestation for its SaaS solutions CONCLUDE CDE and EPLASS CDE. The U.S. SOC 2 security standard (System and Organization Controls 2), which has been defined by the American Institute of Certified Public Accountants (AICPA), is primarily aimed at security in cloud computing, unlike standards such as ISO/IEC 27001. The standard also aims to create maximum information security
